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Although Duchenne muscular dystrophy is primarily categorised as a skeletal muscle disease, deficiency in the membrane cytoskele-
tal protein dystrophin also affects the heart. The central transsarcolemmal linker between the actin membrane cytoskeleton and the
extracellular matrix is represented by the dystrophin-associated dystroglycans. Chemical cross-linking analysis revealed no signif-
icant differences in the dimeric status of the α-/β-dystroglycan subcomplex in the dystrophic mdx heart as compared to normal
cardiac tissue. In analogy to skeletal muscle fibres, heart muscle also exhibited a greatly reduced abundance of both dystroglycans
in dystrophin-deficient cells. Immunoblotting demonstrated that the degree of reduction in α-dystroglycan is more pronounced in
matured mdx skeletal muscle as contrasted to the mdx heart. The fact that the deficiency in dystrophin triggers a similar patho-
biochemical response in both types of muscle suggests that the cardiomyopathic complications observed in x-linked muscular
dystrophy might be initiated by the loss of the dystrophin-associated surface glycoprotein complex.
INTRODUCTION
Dystrophinopathies are caused by mutations in
the dystrophin gene on chromosome Xp21.1 [1] and
comprise severe Duchenne muscular dystrophy, benign
Becker’s muscular dystrophy, and x-linked dilated car-
diomyopathy [2, 3, 4]. Deficiency in the Dp427 isoform
of the membrane cytoskeletal protein dystrophin affects
skeletal muscle, the heart, and the central nervous system
to varying degrees [5, 6, 7]. Cardiac involvement in dys-
trophinopathies is represented by the pathoanatomical re-
placement of cardiac fibres by connective and fatty tissue
[8]. During the clinical progression of Duchenne mus-
cular dystrophy, approximately 90% of patients develop
a serious impairment of cardiac function and cardiomy-
opathy is the cause of death in about 20% of cases [9].
With respect to enhancing our knowledge of the molec-
ular pathogenesis of the most common gender-specific
genetic disease in humans, the significant proportion of
Duchenne patients suffering from cardiac involvement
warrants a detailed investigation of the dystrophic heart
muscle.
In normal muscle fibres, dystrophin is tightly as-
sociated with several surface glycoproteins [10]. The
dystrophin-glycoprotein complex is involved in the sta-
bilisation of the fibre periphery by providing a transsar-
colemmal linkage between the actin membrane cytoskele-
ton and laminin [11]. The central element of this
supramolecular assembly is represented by the dystrogly-
can subcomplex [12]. The extracellular 156 kd glycopro-
tein α-dystroglycan and the integral membrane protein
β-dystroglycan of apparent 43 kd are encoded by a single
mRNA [13]. Since the actin-binding protein dystrophin is
directly linked to β-dystroglycan, which in turn interacts
with the laminin-binding element α-dystroglycan, this
complex provides a linkage between the sarcolemma and
the extracellular matrix. In dystrophin-deficient skeletal
muscle fibres, the dystrophin-associated glycoproteins are
greatly reduced [14] triggering a loss of a proper link-
age between the plasma membrane and the extracellular
matrix component laminin. This pathobiochemical de-
fect is thought to render muscle fibres more susceptible to
surface microrupturing which triggers a Ca2+-dependent
membrane resealing process at the sites of sarcolemmal
disintegration [15]. The newly introduced plasmalemmal
patches contain Ca2+ leak channels causing an increased
flux of Ca2+ ions into the cytoplasm of dystrophic fi-
bres. Increased cytosolic Ca2+ levels then activate Ca2+-
dependent proteases resulting in the net degradation of
muscle proteins in muscular dystrophy [16].
Here we used themdx animal model of x-linked mus-
cular dystrophy [17], which lacks the Dp427 isoform of
dystrophin due to a point mutation in exon 23 [18], to
analyse the fate of the dystroglycan complex in the dys-
trophic heart. Although cardiac mdx fibres do not rep-
resent a perfect replica of the human cardiomyopathic
pathology, several studies have shown that their pheno-
type is of clinical relevancy. The mdx mice exhibit an
abnormal electrocardiogram [19] and their hearts show
necrotic changes and inflammation to a varying degree
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[20]. The mdx heart displays significant tachycardia and
decreased heart rate variability [21], and has markedly al-
tered contractile properties [22]. A progression of the dys-
trophic phenotype is observed inmdx hearts during aging
[23]. Interestingly, physical exercise appears to accelerate
the dystrophic process in cardiac tissues. Exercised mdx
hearts show extensive infiltration of inflammatory cells, as
well as an increase in adipose tissue and interstitial fibro-
sis [24]. This makes it a suitable model system to study the
molecular and cellular effects of deficiency in dystrophin
on cardiac tissues. Our chemical cross-linking analysis
and immunoblotting survey suggests that the lack of car-
diac dystrophin clearly affects the abundance of the α-/β-
dystroglycan complex but not its dimeric status. Hence, in
analogy to skeletal muscle fibres, dystrophic heart mus-
cle also exhibits a greatly reduced abundance of dystro-
glycans suggesting a similar pathobiochemical pathway in
both types of muscle.
MATERIALS ANDMETHODS
Materials
Primary antibodies were obtained from Novocas-
tra Laboratories Ltd, Newcastle upon Tyne, UK (mAb
NCL-43 against β-dystroglycan and mAb DYS-2 to the
carboxy-terminus of the dystrophin isoform Dp427),
Affinity Bioreagents, Golden, Colo (mAb 20A4 to the
α2-subunit of the dihydropyridine receptor, mAb IID8
to the slow/cardiac SERCA2 isoform of the sarcoplas-
mic reticulum Ca2+-ATPase, and mAb C3-33 to the car-
diac RyR2 isoform of the ryanodine receptor Ca2+ re-
lease channel), Sigma Chemical Company, Poole, Dorset,
UK (pAb to laminin), and Upstate Biotechnology, Lake
Placid, NY (mAb C464.6 to the α1-subunit of the Na+/K+-
ATPase and mAb VIA41 to α-dystroglycan). Peroxidase-
conjugated secondary antibodies were from Chemicon
International (Temecula, Calif). Ultrapure Protogel acry-
lamide stock solutions were obtained from National Di-
agnostics (Atlanta, Ga). Chemiluminescence substrates
and chemical cross-linkers were purchased from Perbio
Science UK (Tattenhall, Cheshire). Protran nitrocellu-
lose membranes were from Schleicher and Schuell (Das-
sel, Germany). Protease inhibitors were obtained from
Roche Diagnostics GmbH (Mannheim, Germany). All
other chemicals used were of analytical grade and pur-
chased from Sigma Chemical Company.
Cardiac and skeletal muscle preparations
Hearts and hind limb skeletal muscles from 6-, 8-, 15-,
and 24-week-old mice of the Dmdmdx strain (Jackson
Laboratory, Bar Harbor, Me) and age-matched controls
were obtained through the Biomedical Facility of the Na-
tional University of Ireland, Dublin. Heart muscle spec-
imens from the mdx-3cv animal model were a generous
gift from Dr. Harald Jockusch (University of Bielefeld,
Germany). For two-dimensional immunoblotting, total
protein extracts from dystrophic and age-matched nor-
mal hearts were prepared by the method of Dowling et
al [25]. For chemical cross-linking and one-dimensional
immunoblotting, the crude microsomal membrane frac-
tion was isolated from normal and dystrophic heart
and skeletal muscle specimens by an established proto-
col [26]. All buffers contained a mixture of protease in-
hibitors (0.2mM Pefabloc, 1.4 µM pepstatin A, 0.3 µM E-
64, 1 µM leupeptin, 1mM EDTA, 0.5 µM soybean trypsin
inhibitor) [25] and all preparative steps were performed at
0–4◦C.Membranes were resuspended at a protein concen-
tration of 10mg/mL and used immediately for biochemi-
cal analyses.
Chemical cross-linking analysis
Chemical cross-linking of cardiac membrane pro-
teins was carried out with the 0.15 nm heterobi-
functional probe N-succinimidyl-iodoacetate (SIA) and
the 0.3 nm homobifunctional probe 1, 5-difluoro-2, 4-
dinitrobenzene (DFDNB) using protocols optimised for
muscle membrane proteins [27]. Membranes were in-
cubated for 30minutes at room temperature in 50mM
Hepes, pH 8.0 with 50 µg cross-linker per mg cardiac
protein. Subsequently, the chemical cross-linking reac-
tion was terminated by the addition of 50 µL of 1M am-
monium acetate per mL of reaction mixture [26] and
an equal volume of sodium dodecyl sulfate-containing
sample buffer [28] was added to the suspension. The
mixture was warmed for 10minutes at 37◦C and then
proteins were electrophoretically separated [25]. Cross-
linker-stabilised complexes, as indicated by DFDNB-
induced shifts to a lower electrophoretic mobility, were
determined by immuno-decoration of protein bands.
Immunoblotting
Using a Mini-MP3 electrophoresis system from Bio-
Rad Laboratories (Hemel Hempstead, Hertfordshire,
UK), the gel electrophoretic separation of microsomal
heart and skeletal muscle proteins was carried out un-
der reducing conditions in the presence of sodium dode-
cyl sulfate [28]. Polyacrylamide gels (7% (w/v)) were run
for 280Vh with 25 µg protein per lane. Two-dimensional
gel electrophoresis of total tissue extracts, using isoelectric
focusing in the first dimension and sodium dodecyl sul-
fate gel electrophoresis in the second dimension, was per-
formed as previously described in detail [25]. Themethod
of Towbin et al [29] was employed to electrophoreti-
cally transfer proteins to nitrocellulose paper using a Bio-
Rad Mini-MP3 blotting cell system (Bio-Rad Laborato-
ries). Incubation with 1 : 1 000 diluted primary anti-
bodies, washing steps, incubation with 1 : 1 000 diluted
secondary antibodies, and the visualization of immuno-
decorated protein bands by enhanced chemiluminescence
(ECL) were performed as previously described in detail
[30]. Densitometric scanning of ECL blots was performed
on a Molecular Dynamics 300S computing densitometer
(Sunyvale, Calif) using ImageQuant V3.0 software.
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RESULTS ANDDISCUSSION
A well-established pathobiochemical feature of dys-
trophic skeletal muscle fibres is a drastic reduction in the
expression levels of dystrophin-associated glycoproteins
[5, 11, 14, 31]. In order to determine whether deficiency
in the full-length cardiac Dp427 isoform of dystrophin
has a similar effect on the dystrophic heart, we have bio-
chemically investigated the relative abundance and the
oligomeric status of the backbone of the cardiac dys-
trophin complex, the dystroglycans, using immunoblot-
ting and chemical cross-linking analysis.
REDUCED EXPRESSION OF THE DYSTROGLYCAN
COMPLEX IN DYSTROPHIC HEARTMUSCLE
Prior to an in-depth immunoblotting and chemi-
cal cross-linking analysis comparing the abundance and
oligomeric status of the dystroglycan subcomplex in nor-
mal versus dystrophic heart membranes, the mutant sta-
tus of themdx specimens was confirmed. As illustrated in
Figure 1(a), lane 2, mdx cardiac microsomes completely
lack the Dp427 isoform of dystrophin. Figures 1(b) and
1(c), lane 2, show that mdx hearts exhibit a greatly re-
duced expression of both α- and β-dystroglycan. In con-
trast, the relative density of the extracellular matrix com-
ponent laminin, the surface membrane marker Na+/K+-
ATPase, and the α2-subunit of the transverse-tubular di-
hydropyridine receptor is not markedly changed in the
dystrophic heart (Figures 1(d) to 1(f), lane 2). This shows
that the loss of dystrophin-associated glycoproteins is
most likely due to the specific lack of dystrophin and is
not a consequence of general cardiac muscle fibre degra-
dation. These findings agree with the analysis of another
animal model, the mdx-3cv mouse, that has a mutation
in exon 65 that affects the splicing of both the 4.8 kb
and 14 kb dystrophin mRNAs causing a loss of all dys-
trophin isoforms [32]. Deficiency of full-length cardiac
dystrophin in mdx-3cv membranes causes a similar re-
duction in the α-/β-dystroglycan subcomplex as com-
pared to mdx specimens, while the expression of laminin,
the Na+/K+-ATPase, and the α2-dihydropyridine recep-
tor is not drastically affected (Figures 1(a) to 1(f), lane
3). Since abnormal Ca2+ handling has been proposed to
occur in dystrophic fibres [15, 16], we have performed
an additional immunoblot analysis of two major ion-
regulatory elements in the heart, the sarcoplasmic reticu-
lum Ca2+-ATPase and the Ca2+ release channel. Both car-
diac isoforms, the SERCA2 Ca2+-ATPase and the RyR2
Ca2+ release channel were found to be decreased in their
expression (Figures 1(g) and 1(h), lane 2).
Since subcellular fractionation protocols may intro-
duce artefacts, the immunoblotting analysis of dystro-
glycans was also performed with total cardiac extracts.
As illustrated in Figures 2a and 2b, the two-dimensional
silver-staining pattern of the total protein complement
from normal mouse heart versus dystrophic mdx heart
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Figure 1. Reduced expression of the dystroglycan complex in
dystrophic heart membranes. Shown are immunoblots of nor-
mal (lane 1), 15-week-old mdx (lane 2), and 15-week-old mdx-
3cv (lane 3) cardiac muscle membranes, labelled with antibod-
ies to the Dp427 isoform of dystrophin (a), α-dystroglycan (α-
DG) (b), β-dystroglycan (β-DG) (c), laminin (LAM) (d), the
α-subunit of the Na+/K+-ATPase (NKA) (e), the α2-subunit
of the dihydropyridine receptor (α2-DHPR) (f), the RyR2 iso-
form of the ryanodine receptor Ca2+ release channel (g), and
the slow/cardiac SERCA2 isoform of the sarcoplasmic reticu-
lum Ca2+-ATPase (h). Dystrophin-deficient cardiac microsomes
clearly exhibit a drastic reduction in both dystroglycans.
did not differ significantly. With the exception of a few
low-molecular-mass spots, overall protein expression is
relatively comparable. However, this technique only vi-
sualizes protein species of relatively high abundance and
lacks sensitivity to properly identify proteins that exist at a
low density in cardiac membranes. We therefore used im-
munoblotting to evaluate the status of the dystroglycans
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Figure 2. Reduced expression of the dystroglycan complex in
dystrophic heart muscle. Shown are silver-stained gels ((a), (b))
and identical immunoblots ((c), (d), (e), (f), (g), and (h)) of
24-week-old normal ((a), (c), (e), (g)) and age-matched mdx
((b), (d), (f), (h)) total heart extracts. Immunoblots were la-
belled with antibodies to the α2-subunit of the dihydropyridine
receptor (α2-DHPR) ((c), (d)), α-dystroglycan (α-DG) ((e), (f)),
and β-dystroglycan (β-DG) ((g), (h)). The position of immuno-
decorated spots is marked by arrow heads. The pH values of the
first-dimensional gel system and molecular mass standards (in
kd) of the second dimension are indicated on the top and on the
left of the panels, respectively.
in total cardiac fibre extracts. In agreement with our find-
ings from one-dimensional immunoblotting of micro-
somes (Figure 1(f)), the expression of the α2-subunit of
the dihydropyridine receptor was found not to be af-
fected in dystrophin-deficient mdx heart as judged by
two-dimensional immunoblotting of total tissue extracts
(Figures 2(c), 2(d)). In contrast, the immuno-decoration
of α-dystroglycan (Figures 2(e), 2(f)) and β-dystroglycan
(Figures 2(g), 2(h)) revealed a clear reduction of both
proteins in the dystrophic heart. This agrees with the
above-described analysis of cardiac membrane prepara-
tions from normal heart and mdx heart. The loss in
membrane-associated dystroglycans is therefore not lim-
ited to a dissociation from the fibre periphery, but proba-
bly also includes a rapid degradation of unbound dystro-
glycans in the cytosol. If dystrophin is missing as a molec-
ular anchor in the sarcolemma and transverse tubules of
cardiac fibres, dystroglycan units appear to dissociate and
subsequently disintegrate.
CHEMICAL CROSS-LINKING ANALYSIS OF THE
CARDIAC DYSTROGLYCAN COMPLEX
Chemical cross-linking is an established biochemi-
cal technique for the analysis of multimolecular aggre-
gates in biological membranes [33], widely employed for
the elucidation of the quaternary structure of oligomeric
proteins and their native organisation in membrane
systems [34]. Cross-linkers of various length and sol-
ubility such as N-succinimidyl-iodoacetate (SIA) and
1,5-difluoro-2,4-dinitrobenzene (DFDNB) have been es-
tablished as effective tools and immunoblotting has
proven to be highly suitable for the analysis of cross-linked
products. While DFNB reacts with primary amines, SIA
contains an amine-reactive functional group at one end
and a sulfhydryl-active group at the other end. In order
to keep artefacts of random cross-linking and hydrolysis
of cross-linkers to a minimum, it is essential to use con-
trolled conditions with respect to concentration ratios be-
tween membrane proteins and cross-linkers, buffer com-
position, temperature, pH, and length of incubation time
[35]. These parameters have been previously optimised by
our laboratory for muscle membrane proteins in order to
achieve highly reproducible and optimal results with rela-
tively small amounts of muscle tissue [25, 36, 37, 38].
In order to determine whether the reduction in
dystrophin-associated glycoproteins has a modulatory ef-
fect on protein-protein interactions within the remain-
ing surface assembly, chemical cross-linking was per-
formed with cardiac membranes. The 0.3 nm cross-
linker probe DFDNB clearly induced a shift of the α-
dystroglycan protein band to a slower electrophoretic
mobility (Figure 3(a)) indicating stabilisation of the na-
tive membrane complex. In analogy, the monomeric
43 kd β-dystroglycan species was also cross-linked to
a high-molecular-mass complex (Figure 3(b)), whereby
the bands representing the two different dystroglycans
clearly overlapped following treatment with DFDNB (Fig-
ures 3(a), 3(b)). Hence, the cross-linker-stabilised band
of approximately 200 kd probably consists of the α-/β-
dystroglycan dimer. The cross-linker-induced band of ap-
parent 600 kd possibly represents a complex between dys-
trophin of 427 kd and the 200 kd dystroglycan dimer. A
weak band of extremely high molecular mass might con-
sist of the entire dystrophin-glycoprotein complex. An
important control experiment was performed with the
shorter probe SIA that exhibits a spacer arm length of
0.15 nm. This cross-linker can capture functional groups
only in very close proximity, probably too short for
the proper stabilisation of the dystroglycan membrane
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Figure 3. Chemical cross-linking analysis of cardiac dystroglycan complex. Shown are immunoblots of normal ((a), (b)) and mdx
((c), (d)) membranes from 15-week-old mice labelled with antibodies to α-dystroglycan (α-DG) ((a), (c)) and β-dystroglycan (β-DG)
((b), (d)). Lanes from 1 to 3 represent cardiac membranes incubated with no cross-linker probe (control), with 50 µg cross-linker N-
succinimidyl-iodoacetate (XL-SIA) and 50 µg cross-linker 1, 5-difluoro-2, 4-dinitrobenzene (XL-DFDNB) per mg membrane protein,
respectively. Monomeric immuno-decorated protein bands are indicated by arrow heads and cross-linker-stabilised oligomeric forms
are marked by arrows. For the direct comparison of cross-linker-induced changes in the electrophoretic mobility of dystroglycans,
equal amounts of dystroglycan molecules were analysed. Hence, a higher concentration of mdx membranes was used to perform
chemical cross-linking as compared to normal membranes. Molecular mass standards (×10−3) are indicated on the left.
complex (Figures 3(a), 3(b)). The second β-dystroglycan-
positive band of higher molecular mass probably repre-
sents a dimerisation of the 43 kd dystrophin-associated
glycoprotein (Figures 3(b), 3(d); lane 2). Therefore, the
DFDNB-induced oligomerisation of α-/β-dystroglycan is
probably not due to nonspecific aggregation, but a result
of controlled stabilisation via a cross-linker probe with
the optimum reactive functional groups and spacer arm
length. On the other hand, the absence of accessible bind-
ing groups in dystroglycans might also be a reason for the
lack of the formation of very-high-molecular-mass bands
by SIA.
Interestingly, a slightly different pattern of band shift-
ing was observed with cardiac mdx membranes following
incubation with the 0.3 nm probe DFDNB (Figure 3(d)).
The high-molecular-mass band of β-dystroglycan was
weaker in dystrophin-deficient membranes as compared
to normal vesicles (Figures 3(c), 3(d); lane 3). If the cross-
linker-induced band of 600 kd contains dystrophin and
the two dystroglycans, this would indicate a potential
difference in the interaction of β-dystroglycan and the
Dp427 isoform inmuscular dystrophy. However, chemical
cross-linking is a relatively crude biochemical technique
for determining subtle changes in protein-protein inter-
actions and more refined biochemical analyses would be
necessary to clarify this point. Overall, the immunoblot-
ting and cross-linking analysis indicates that the defi-
ciency in cardiac dystrophin causes a severe reduction in
the levels of membrane-associated α- and β-dystroglycan,
but has no major effect on the oligomeric status of the
dimeric dystroglycan complex.
COMPARATIVE ANALYSIS OF DYSTROGLYCAN
EXPRESSION IN DYSTROPHIC HEART
AND SKELETALMUSCLE
Based on the initial immunoblot analysis of dystro-
glycans in dystrophin-deficient heart (Figure 1), we per-
formed a more in-depth study of dystroglycan expression
profiles in differing age groups of the mdx model. To de-
termine potential differences in the degree of reduced ex-
pression of dystroglycans between maturing mdx cardiac
muscle andmdx skeletal muscle, membranes were isolated
from 6-week-, 8-week-, and 24-week-old animals. Mem-
branes isolated from younger animals did not result in
the isolation of sufficient material for proper immuno-
decoration above background levels (not shown). We
therefore focused our investigation on 6- to 24-week-
old muscle fibres. The graphical presentation of the den-
sitometric analysis of immuno-decorated protein bands,
visualised by enhanced chemiluminescence, shows rela-
tively comparable levels of laminin expression in nor-
mal versus dystrophic specimens from both the heart and
skeletal muscles (Figure 4(a) and (b)). In stark contrast,
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Figure 4. Comparative immunoblot analysis of dystroglycan expression in dystrophic heart and skeletal muscle. Shown is the graph-
ical presentation of the immuno-decoration of laminin ((a),(b)), α-dystroglycan ((c),(d)), and β-dystroglycan ((e),(f)) in normal
(black bars) and dystrophicmdx (grey bars) membrane preparations from both skeletal ((a),(c),(e)) and cardiac ((b),(d),(f)) muscles
(n = 5; SEM; ∗P < .05; ∗∗P < .01; ∗∗∗P < .001). Specimens were taken from 6-, 8-, and 24-week-(w-)old mice.
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both dystroglycans are drastically reduced in dystrophic
mdx tissues. Both α- and β-dystroglycan exhibited a grad-
ual decrease in their expression during tissue matura-
tion (Figure 4(c)–(f)). The degree of reduction in α-
dystroglycan is more pronounced in matured 24-week-
old mdx skeletal muscle as contrasted to the age-matched
mdx heart (Figure 4(c) and (d)).
MOLECULAR PATHOGENESIS OFMUSCULAR
DYSTROPHY-ASSOCIATED CARDIOMYOPATHY
The results of the immunoblot analysis presented
in this report indicate that the loss of the Dp427 iso-
form of dystrophin triggers a similar pathobiochemical
response in skeletal muscle and the heart. Our biochem-
ical findings agree with the recent analysis of dystrogly-
can expression in dystrophic heart muscle fibres by im-
munofluorescence microscopy [39, 40]. Thus, cardiomy-
opathic complications associated with x-linked muscu-
lar dystrophy might be initiated by a reduced presence
of β-dystroglycan in the cellular periphery. We could re-
cently show that the degree of β-dystroglycan reduction is
a relative good indicator of the severity of fibre degener-
ation in skeletal muscles [25]. Despite a proper dimerisa-
tion of the dystroglycans, an overall loss of dystroglycan
units would trigger a diminished linkage between the ex-
tracellular matrix and the actin membrane cytoskeleton.
This probably renders cardiac muscle fibres more suscep-
tible to microrupturing of the surface membrane during
excitation-contraction-relaxation cycles eventually lead-
ing to cellular necrosis. However, since the subcellular
distribution of the dystrophin-glycoprotein is not iden-
tical between the heart and skeletal muscles [41], the ex-
act histopathological mechanism might vary slightly. In
the heart, dystrophin-associated complexes are not re-
stricted to the sarcolemma, as in the case of skeletal mus-
cle, but also localise to the transverse-tubular region of the
surface membrane [41, 42]. Thus, contraction-induced
membrane rupturing might affect both the plasmalemma
and transverse tubules of the dystrophin-deficient car-
diac fibre periphery. In analogy to the calcium hypoth-
esis of skeletal muscular dystrophy [15, 16], possibly re-
sealing of disrupted membrane patches might also intro-
duce Ca2+ leak channels into the dystrophic heart surface
membrane. This could lead to raised cytosolic Ca2+ lev-
els and the activation of Ca2+-dependent proteases caus-
ing fibre destruction. In this respect, our immunoblot-
ting result showing a decreased expression of the car-
diac RyR2 isoform of the ryanodine receptor Ca2+ release
channel and the slow/cardiac SERCA2 isoform of the sar-
coplasmic reticulum Ca2+-ATPase agrees with a recent re-
port by Rohman et al [43] that demonstrated a decreased
gene expression of both Ca2+ regulatory elements. This
suggests that abnormal Ca2+ handling in the dystrophic
heart possibly leads to impaired excitation-contraction
coupling and cardiac relaxation cycles. It will be of con-
siderable interest to further establish any potential abnor-
malities in the Ca2+ regulatory apparatus of the dystrophic
heart. One potential way forward is the use of proteomics
research tools such as the global comparative survey of
normal versus dystrophic cardiac tissues employing high-
resolution two-dimensional gel electrophoresis in com-
bination with mass spectroscopy. This might lead to the
identification of novel candidate proteins involved in the
downstream events of x-linked muscular dystrophy and
thereby identify new therapeutic targets.
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